AR024837A1 - Derivados de n-(iminometil)aminas, compuestos intermediarios para su preparacion, medicamento y composicion farmaceutica que los contienen y uso de dichos derivados para la produccion de medicamentos. - Google Patents
Derivados de n-(iminometil)aminas, compuestos intermediarios para su preparacion, medicamento y composicion farmaceutica que los contienen y uso de dichos derivados para la produccion de medicamentos.Info
- Publication number
- AR024837A1 AR024837A1 ARP990104748A ARP990104748A AR024837A1 AR 024837 A1 AR024837 A1 AR 024837A1 AR P990104748 A ARP990104748 A AR P990104748A AR P990104748 A ARP990104748 A AR P990104748A AR 024837 A1 AR024837 A1 AR 024837A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- derivatives
- chosen
- carbon atoms
- linear
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003254 radicals Chemical class 0.000 abstract 8
- -1 aminophenyl amine Chemical class 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 abstract 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 abstract 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000005840 aryl radicals Chemical class 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 239000013626 chemical specie Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000007310 pathophysiology Effects 0.000 abstract 1
- 229950000688 phenothiazine Drugs 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
Abstract
Derivados de N-(iminometil)aminas que en su esqueleto comprenden la unidad aminofenil amina, oxidifenil amina, carbazol, fenazina, fenotiazina uoxidifenilo. Estos derivados responden a la formula general (1). En donde Fi representa un enlace o unrad ical fenileno que puede incluir, además de las doscadenas ya representadas en la formula general (1), hasta dos sustituyentes elegidos de entre un átomo de hidrogeno, un halogeno, un grupo OH, y un radicalalquilo o alcoxi, lineal o ramificado,que ti ene de 1 a 6 átomos de carbono; A representa un radical de formula (2) o un radical de formula (3). B representa-CH2-NO2, un radical alquilo lineal o ramificado que tiene de 1 a 6 átomos de carbono, arilo carbocíclico o heterocíclico con 5 o6 miemb ros que contiene de 1a 4 heteroátomos elegidos entre O, S, N y en particular el radical tiofeno, furano, pirrol o tiazol, estando el radical arilo opcionalmente sustituido por unoo más grupos elegidos entre los radicales alquilo, alquenilo oalcoxi, lineales o ramificados, que tienen de 1 a 6 átomos de carbono, o B representa un radicalNR13R14; X representa un enlace o un radical (CH2)k-NR16, -O-, -S-, -CO-, NR16-CO-, CO-NR16, -O-CO-, -CO-O-, -NR16-CO-O, -NR16-CO-NR17-, Y representa unenlaceo u n radical elegido entre los radicales -(CH2)m, -(CH2)m-O-(CH2)n-, -(CH2)m-S-(CH2)n-, -(CH2)m-NR18-(CH2)n-, -(CH2)mNR18-CO-(CH2)N-, -(CH2)m-CO-NR18-(CH2)n-,-(CH2)-Q-(CH2)n-; donde los restantes sustituyentes están definidos en la memoriadescriptiva. Estos derivados presentan una actividad inhibidora sobre lasenzimas NO-sintasas que producen el monoxido de nitrogeno, NO, y/o una actividad que entrampa las especies oxígeno reactivas (ROS reactive oxygen species).Dadoel rol potencialdel NO y de lo s ROS en la fisiopatología, los derivados descriptos correspondientes a la formula general(1) pueden producir efectosbeneficiosos o favorables en el tratamiento de patologías en las cuales intervienen estas especies químicas enparticular su uso como inhibidores de la NO-sintasa y como trampas, selectivas o no; de las especies de oxígeno reactivas. Comprende además a los medicamentos y composiciones farmacéuticas que contienen a
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9811867A FR2784678B1 (fr) | 1998-09-23 | 1998-09-23 | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024837A1 true AR024837A1 (es) | 2002-10-30 |
Family
ID=9530743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104748A AR024837A1 (es) | 1998-09-23 | 1999-09-21 | Derivados de n-(iminometil)aminas, compuestos intermediarios para su preparacion, medicamento y composicion farmaceutica que los contienen y uso de dichos derivados para la produccion de medicamentos. |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US6482822B1 (es) |
| EP (1) | EP1115720B1 (es) |
| JP (1) | JP2003517444A (es) |
| KR (1) | KR100655340B1 (es) |
| CN (1) | CN1144799C (es) |
| AR (1) | AR024837A1 (es) |
| AT (1) | ATE399774T1 (es) |
| AU (1) | AU759958B2 (es) |
| BR (1) | BR9913899A (es) |
| CA (1) | CA2344223A1 (es) |
| CZ (1) | CZ299664B6 (es) |
| DE (1) | DE69939021D1 (es) |
| DK (1) | DK1115720T3 (es) |
| ES (1) | ES2310045T3 (es) |
| FR (1) | FR2784678B1 (es) |
| HK (1) | HK1043365B (es) |
| HU (1) | HUP0104013A3 (es) |
| IL (2) | IL141997A0 (es) |
| MY (1) | MY123219A (es) |
| NO (1) | NO328466B1 (es) |
| NZ (1) | NZ511188A (es) |
| PL (1) | PL347471A1 (es) |
| PT (1) | PT1115720E (es) |
| RU (1) | RU2230742C2 (es) |
| WO (1) | WO2000017191A2 (es) |
| ZA (1) | ZA200103206B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ3415A1 (fr) | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| FR2815030A1 (fr) * | 2000-10-05 | 2002-04-12 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments |
| WO2002081443A1 (en) | 2001-04-09 | 2002-10-17 | Chiron Corporation | Novel guanidino compounds |
| MXPA04011557A (es) | 2002-05-23 | 2005-07-05 | Chiron Corp | Compuestos de quinazolinona sustituida. |
| PT1470818E (pt) * | 2003-04-25 | 2006-11-30 | Neuro3D | Utilização de derivados de fenotiazina piperazina no fabrico de um medicamento com efeitos neuroprotectores e/ou neurotróficos no cns e/ou pns |
| EP1651229A1 (en) | 2003-05-23 | 2006-05-03 | Chiron Corporation | Guanidino-substituted quinazolinone compounds as mc4-r agonists |
| EP1686996A4 (en) | 2003-11-19 | 2008-11-12 | Novartis Vaccines & Diagnostic | CHINAZOLINONE COMPOUNDS WITH REDUCED BIOAC CUMULATION |
| EP1716867A4 (en) * | 2004-02-20 | 2009-09-23 | Astellas Pharma Inc | PRENENT AGENTS FOR MIGRAINE |
| TW200614995A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors |
| RS54876B1 (sr) | 2005-05-10 | 2016-10-31 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| ES2371106T3 (es) | 2005-08-08 | 2011-12-27 | Astellas Pharma Inc. | Derivado de acilguanidina o sal del mismo. |
| RU2428983C2 (ru) * | 2005-09-02 | 2011-09-20 | Санесис Фармасьютикалз, Инк. | Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака |
| KR20170118936A (ko) * | 2005-09-02 | 2017-10-25 | 선에시스 파마슈티컬스 인코포레이티드 | 암 치료를 위한 (＋)-1,4-디히드로-7-［(3ｓ,4ｓ)-3-메톡시-4-(메틸아미노)-1-피롤리디닐］-4-옥소-1-(2-티아졸릴)-1,8-나프티리딘-3-카르복실산의 사용 방법 |
| US20070093548A1 (en) * | 2005-10-25 | 2007-04-26 | Wyeth | Use of progesterone receptor modulators |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US7772306B2 (en) * | 2006-07-18 | 2010-08-10 | Glustitch, Inc. | Cyanoacrylate compositions having increased stability under irradiation |
| GB0614365D0 (en) * | 2006-07-19 | 2006-08-30 | Proaxon Ltd | Pharmaceutical compositions and their use |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008096791A1 (ja) | 2007-02-07 | 2008-08-14 | Astellas Pharma Inc. | アシルグアニジン誘導体 |
| DK2315756T5 (en) | 2008-07-08 | 2015-08-03 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
| MX345654B (es) * | 2009-09-14 | 2017-02-08 | The Procter & Gamble Company * | Composición detergente compacta fluida para lavandería. |
| WO2012053281A1 (ja) | 2010-10-22 | 2012-04-26 | 株式会社エクセディ | クラッチ装置 |
| CN104119295B (zh) * | 2013-04-27 | 2018-04-10 | 天津药物研究院 | 吩噻嗪类一氧化氮供体、其制备方法和用途 |
| TWI651311B (zh) | 2013-11-08 | 2019-02-21 | 英塞特控股公司 | 用於合成吲哚胺２，３－雙加氧酶抑制劑之方法 |
| US10247741B2 (en) | 2014-09-26 | 2019-04-02 | Abbott Point Of Care Inc. | Microfabricated device with micro-environment sensors for assaying coagulation in fluid samples |
| WO2016049545A1 (en) | 2014-09-26 | 2016-03-31 | Abbott Point Of Care Inc. | Single channel cartridge device for coagulation assays in fluid samples |
| CN106999932A (zh) | 2014-09-26 | 2017-08-01 | 雅培医护站股份有限公司 | 用于流体样本中的凝结测定的具有流体结的盒设备 |
| EP3198272B1 (en) | 2014-09-26 | 2022-04-06 | Abbott Point Of Care, Inc. | Cartridge device identification for coagulation assays in fluid samples |
| US10048281B2 (en) | 2014-09-26 | 2018-08-14 | Abbott Point Of Care Inc. | Cartridge device with segmented fluidics for assaying coagulation in fluid samples |
| EP3198281B1 (en) | 2014-09-26 | 2023-01-25 | Abbott Point Of Care, Inc. | Ellagic acid formulations for use in coagulation assays |
| WO2016049506A1 (en) | 2014-09-26 | 2016-03-31 | Abbott Point Of Care Inc. | Sensors for assaying coagulation in fluid samples |
| US10882821B1 (en) | 2017-09-26 | 2021-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
| JP7433292B2 (ja) * | 2018-04-27 | 2024-02-19 | チョンドゥー ホンハオ インベストメント カンパニー リミテッド | １０ｈ－フェノチアジン系フェロトーシス阻害剤、その製造方法、及び用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7412024A (nl) * | 1973-09-15 | 1975-03-18 | Hoechst Ag | Werkwijze voor het verven en bedrukken van cellulosehoudende textielmaterialen. |
| JPS51103131A (ja) * | 1975-03-08 | 1976-09-11 | Teijin Ltd | Oshokukinofutaronkeiganryono seizohoho |
| GB1571506A (en) * | 1976-02-23 | 1980-07-16 | Agfa Gevaert | 4-phenyl azo - 2 - pyrazolin - 5 - one colour coupler and their use in photography |
| DE3061860D1 (en) * | 1979-04-24 | 1983-03-17 | Marcel Jozefonvicz | Process for the determination of proteases and antiproteases |
| WO1994014780A1 (en) * | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
| DE69418601T2 (de) * | 1993-03-23 | 1999-09-30 | Astra Aktiebolag, Soedertaelje | Guanidinderivate mit therapeutischer wirkung |
| GB9312761D0 (en) * | 1993-06-21 | 1993-08-04 | Wellcome Found | Amino acid derivatives |
| IL110643A (en) * | 1993-08-12 | 1998-07-15 | Astra Ab | Amidine derivatives their preparation and pharmaceutical compositions containing them |
| CA2188680A1 (en) * | 1994-05-07 | 1996-01-25 | James Edwin Macdonald | Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase |
| AU2629795A (en) * | 1994-12-12 | 1996-07-03 | Chugai Seiyaku Kabushiki Kaisha | Aniline derivative having the effect of inhibiting nitrogen monoxide synthase |
| FR2761066B1 (fr) * | 1997-03-24 | 2000-11-24 | Sod Conseils Rech Applic | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| DE69907476T2 (de) * | 1998-08-20 | 2004-04-15 | The University Of North Carolina At Chapel Hill Office Of Technology Development | Dibenzothiophene derivate und ihre verwendung |
-
1998
- 1998-09-23 FR FR9811867A patent/FR2784678B1/fr not_active Expired - Fee Related
-
1999
- 1999-09-21 AR ARP990104748A patent/AR024837A1/es active IP Right Grant
- 1999-09-22 DE DE69939021T patent/DE69939021D1/de not_active Expired - Lifetime
- 1999-09-22 AU AU56315/99A patent/AU759958B2/en not_active Ceased
- 1999-09-22 CN CNB998127523A patent/CN1144799C/zh not_active Expired - Fee Related
- 1999-09-22 IL IL14199799A patent/IL141997A0/xx unknown
- 1999-09-22 CZ CZ20011056A patent/CZ299664B6/cs not_active IP Right Cessation
- 1999-09-22 HU HU0104013A patent/HUP0104013A3/hu unknown
- 1999-09-22 PT PT99943025T patent/PT1115720E/pt unknown
- 1999-09-22 RU RU2001111023/04A patent/RU2230742C2/ru not_active IP Right Cessation
- 1999-09-22 EP EP99943025A patent/EP1115720B1/fr not_active Expired - Lifetime
- 1999-09-22 AT AT99943025T patent/ATE399774T1/de not_active IP Right Cessation
- 1999-09-22 DK DK99943025T patent/DK1115720T3/da active
- 1999-09-22 KR KR1020017003670A patent/KR100655340B1/ko not_active Expired - Fee Related
- 1999-09-22 JP JP2000574100A patent/JP2003517444A/ja active Pending
- 1999-09-22 PL PL99347471A patent/PL347471A1/xx unknown
- 1999-09-22 ES ES99943025T patent/ES2310045T3/es not_active Expired - Lifetime
- 1999-09-22 CA CA002344223A patent/CA2344223A1/fr not_active Abandoned
- 1999-09-22 HK HK02105058.6A patent/HK1043365B/zh not_active IP Right Cessation
- 1999-09-22 NZ NZ511188A patent/NZ511188A/en not_active IP Right Cessation
- 1999-09-22 BR BR9913899-9A patent/BR9913899A/pt not_active Application Discontinuation
- 1999-09-22 MY MYPI99004105A patent/MY123219A/en unknown
- 1999-09-22 WO PCT/FR1999/002251 patent/WO2000017191A2/fr not_active Ceased
- 1999-09-22 US US09/787,466 patent/US6482822B1/en not_active Expired - Fee Related
-
2001
- 2001-03-13 IL IL141997A patent/IL141997A/en not_active IP Right Cessation
- 2001-03-22 NO NO20011478A patent/NO328466B1/no not_active IP Right Cessation
- 2001-04-19 ZA ZA200103206A patent/ZA200103206B/en unknown
-
2002
- 2002-09-26 US US10/255,849 patent/US6620840B1/en not_active Expired - Fee Related
-
2003
- 2003-07-01 US US10/612,646 patent/US6809090B2/en not_active Expired - Fee Related
-
2004
- 2004-07-21 US US10/895,578 patent/US20050027009A1/en not_active Abandoned
-
2005
- 2005-04-26 US US11/114,803 patent/US7186752B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024837A1 (es) | Derivados de n-(iminometil)aminas, compuestos intermediarios para su preparacion, medicamento y composicion farmaceutica que los contienen y uso de dichos derivados para la produccion de medicamentos. | |
| DE60132309D1 (de) | Amin-derivate zur behandlung von apoptosis | |
| ECSP23095485A (es) | N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio | |
| AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| ATE233730T1 (de) | Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung | |
| AR033499A1 (es) | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente | |
| IL149163A0 (en) | Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| SE0202133D0 (sv) | Novel compounds | |
| ATE158288T1 (de) | Antiatherosklerotische und antithrombotische 1- benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on- derivate | |
| AR035455A1 (es) | Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos | |
| TR199901765T2 (xx) | S�lfomid-metalloproteaz inhibit�rleri | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| MA21864A1 (fr) | Lauramides n-substitues, leur preparation et compositions les contenant | |
| NI200900147A (es) | Nuevos derivados tricíclicos su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| AR024918A1 (es) | Derivados de ciclobuteno, su preparacion y sus usos terapeuticos. | |
| ATE251624T1 (de) | Granulatimide-derivate zur behandlung von krebs | |
| TR200101978T2 (tr) | 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri. | |
| UA50711C2 (uk) | Антрациклінові похідні, їх застосування при лікуванні амілоїдозу та фармацевтична композиція | |
| EA200001006A1 (ru) | Новые порфирины и их применение | |
| AR004413A1 (es) | Compuestos de tiol que poseen actividad inhibitoria de metalopeptidasa; proceso para preparar dichos derivados; composiciones farmaceuticas que loscontienen | |
| DE69933885D1 (de) | Triphenylbutenderivate zur behandlung von neurologischen störungen | |
| SE0303090D0 (sv) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |